The MHRA's approval of the UK's first oral GLP-1 receptor agonist tablet for weight loss represents a significant moment for patients and prescribers alike. With an estimated 2.5 million adults already using weight-loss injections in the UK, demand for a tablet alternative is expected to be considerable.

But alongside the clinical opportunity comes a risk that the medico-legal and insurance sectors cannot afford to overlook: the rapid and well-documented growth of counterfeit weight-loss pharmaceuticals, and the profound implications that presents for clinical indemnity and insurer exposure.

The counterfeit landscape

Counterfeit injectables have already demonstrated that criminal networks are willing and able to exploit demand for GLP-1 treatments. The transition to oral tablets is likely to make that problem significantly worse. Unlike injectable pens, which require complex delivery mechanisms, cold-chain logistics, and manufacturing precision, tablets are easier to produce, package, and distribute through conventional channels, including online marketplaces, social media platforms, and postal services.

The methods available to counterfeiters are sophisticated and varied. Falsified pharmaceuticals may be produced in unregulated laboratories, diverted from legitimate supply chains, or repackaged under the name of a genuine brand. Fake labels, certifications, invoices, and falsified prescriptions are all tools used to introduce counterfeit products into distribution. The result is a landscape in which appearance alone is an increasingly unreliable guide to authenticity and in which the harm that follows falls, ultimately, on patients.

What this means for patient safety and legal liability

The clinical consequences of a patient consuming a counterfeit GLP-1 tablet could be severe. A falsified product offers no reliable assurance as to its contents. It may contain the wrong active compound, an incorrect dose, or harmful contaminants. The consequences range from treatment failure, with the associated metabolic and cardiovascular risks for patients who believe they are being treated, to acute toxicity from unlicensed substances.

From a legal perspective, this creates complex questions around causation and duty of care. Where a patient suffers harm, identifying whether a counterfeit medicine was the operative cause, and establishing which party in the chain owed and breached a relevant duty, will be far from straightforward. The involvement of unregulated online channels, multiple international distribution steps, and sophisticated falsification techniques means that traditional product liability and clinical negligence frameworks will be tested in ways that are not yet fully mapped.

Indemnity exposure for clinicians

For individual clinicians, particularly those operating in private practice or aesthetic medicine settings where GLP-1 treatments are increasingly prescribed, the indemnity implications are significant and, as yet, largely unexplored.

Where the clinician prescribes legitimately but the patient self-sources

A growing number of patients are obtaining GLP-1 treatments, whether injectable or oral, through unregulated online channels after receiving a prescription, or without a prescription at all. Where a patient is harmed by a counterfeit product obtained in this way, the question of whether the prescribing clinician bears any liability will turn on whether they adequately warned the patient of the risks of sourcing medication outside regulated dispensing channels. If that warning was not given, or cannot be evidenced, a clinician could find themselves drawn into proceedings even where they played no direct role in the supply of the counterfeit product.

Critically, clinicians in this position will need to consider whether their indemnity arrangements respond to such a claim. Many medical indemnity policies are drafted by reference to clinical acts and omissions in the course of treatment. A claim arising from a failure to warn about supply chain risks or from the downstream consequences of a patient's own procurement decisions may not sit neatly within standard policy language. Clinicians should seek clarity from their indemnity provider on whether such scenarios are covered.

Where the clinician operates in an unregulated or lightly regulated setting

Private and aesthetic medicine practitioners prescribing weight-loss treatments outside NHS structures face particular scrutiny. Regulatory oversight in these settings can be less stringent, and the patient population may include individuals who are actively seeking to bypass conventional medical channels.

If a clinician prescribes in circumstances where they ought to have known the patient was likely to source medication through unregulated means, regulatory and civil liability could follow with indemnity cover potentially at risk if the circumstances are found to fall outside the policy terms or to involve conduct that the insurer can characterise as reckless.

Online prescribers

The volume of GLP-1 prescriptions now issued through digital health platforms raises additional questions. Where an online prescriber issues a prescription that is subsequently fulfilled through an unauthorised channel, and the patient is harmed as a result, whether that prescriber owes a duty to take reasonable steps to ensure the patient accesses medication through a regulated pharmacy is a question that has not yet been authoritatively answered.

As claims in this area emerge, indemnity providers covering online prescribing platforms should expect to see these arguments advanced.

Insurer exposure: Product liability and supply chain risk

For insurers covering pharmaceutical manufacturers, distributors, and pharmacies, the counterfeit GLP-1 risk raises a distinct set of concerns.

Product liability and the legitimate supply chain

Where a counterfeit product enters a legitimate distribution channel through diversion, relabelling, or falsified documentation, and causes harm to a patient, questions of product liability will arise. Insurers covering pharmaceutical companies and distributors will need to consider whether their policy terms adequately address the scenario in which harm is caused not by a defect in the insured's own product, but by a falsified product that has been introduced into or alongside the legitimate supply chain. The interaction between the Consumer Protection Act 1987, the Human Medicines Regulations 2012, and general tortious liability is likely to be a contested area as claims develop.

Policy review and risk assessment

Insurers providing product liability cover to pharmaceutical companies, wholesale distributors, and pharmacies should be reviewing their policy terms in light of the specific and well-documented counterfeit risk associated with GLP-1 treatments. In particular:

• Whether existing policy language covers losses arising from counterfeit products entering the supply chain through diversion or falsification, as distinct from manufacturing defects in the insured's own products.
• Whether exclusions for unlicensed or unregulated distribution channels are appropriately drafted and will operate as intended.
• Whether sub-limits or specific conditions ought to apply to GLP-1 product lines given the heightened and publicly acknowledged counterfeit risk.
• Whether indemnity arrangements for online prescribing platforms and digital health providers adequately reflect the supply chain risks associated with their prescribing model.

The role of authentication and traceability in risk mitigation

From an underwriting perspective, the measures available to pharmaceutical companies to protect supply chain integrity, including physical authentication technologies, unique product identifiers, and centralised traceability systems, are directly relevant to risk assessment.

Insurers may wish to consider whether the adoption of such measures ought to be reflected in underwriting criteria or policy conditions for pharmaceutical product liability risks, particularly as oral GLP-1 treatments become more widely distributed. Where an insured has failed to implement available and proportionate authentication measures in a market where the counterfeit risk is well-publicised, that failure may be relevant both to liability exposure and to questions of contribution or subrogation.

Conclusion

The approval of oral GLP-1 treatments is a welcome development for patients, but it arrives in a market that criminal networks are already exploiting. For clinicians, indemnity providers, and pharmaceutical insurers, the counterfeit risk is not a future concern; it is a present one that demands attention now. Indemnity policies should be reviewed for adequacy in light of the specific scenarios that counterfeit weight-loss medicines are likely to generate. Insurers covering supply chain and product liability risks should be reassessing their exposure and engaging with their insureds on the authentication and traceability measures available to reduce it.

The cost of counterfeit medicines is ultimately borne by patients. But the legal and financial consequences will be distributed across the clinical, regulatory, and insurance landscape in ways that those operating in it should begin to anticipate. To discuss these implications of GLP-1 further, please contact our specialist product safety and liability team.

This article is intended for general information purposes and does not constitute legal advice. Specific advice should be sought in relation to individual circumstances.